An announcement from Shuttle Pharmaceuticals Holdings, Inc. ( (SHPH) ) is now available.
Shuttle Pharmaceuticals Holdings, Inc. has successfully closed a public offering, raising approximately $4.5 million to support clinical trials, including $2.3 million earmarked for Phase II trials of their radiation sensitizer, Ropidoxuridine. This offering, priced at $1.525 per share with accompanying warrants, aims to bolster the company’s efforts in developing therapies to enhance radiation therapy outcomes for cancer patients. Leading placement agents A.G.P./Alliance Global Partners and Boustead Securities facilitated the offering, which is expected to advance Shuttle Pharma’s clinical development initiatives.
See more data about SHPH stock on TipRanks’ Stock Analysis page.
